Neuromyelitis Optica (NMO) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Neuromyelitis Optica (NMO) Market Outlook

Thelansis’s “Neuromyelitis Optica (NMO) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuromyelitis Optica (NMO) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Neuromyelitis Optica (NMO) Overview

Neuromyelitis optica (NMO), also known as Devic syndrome, manifests as a clinical syndrome characterized by recurrent acute optic neuritis and transverse myelitis. In the majority of patients, NMO is driven by pathogenic serum IgG autoantibodies targeting aquaporin 4 (AQP4), which happens to be the most prevalent water-channel protein within the central nervous system (CNS). In more than 80% of cases, NMO is a result of the presence of pathogenic IgG autoantibodies directed against aquaporin 4 (AQP4-IgG), the predominant water channel protein in the CNS. Roughly 10–40% of individuals diagnosed with NMO who do not possess AQP4-IgG instead have IgG autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG-IgG). Notably, MOG-IgG is also detected in a subgroup of patients, primarily children, with acute disseminated encephalomyelitis (ADEM). The most prominent risk factor for NMO is gender, with a strong association observed in females, particularly in those with AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD). NMO can manifest at any age, with a median age at onset of 40 years for AQP4-IgG-positive patients and 31 years for MOG-IgG-positive patients. It is more prevalent in women than men, especially among those with AQP4-IgG (male-to-female ratio ranging from 1:9 to 1:10). This gender discrepancy is less pronounced in patients with seronegative NMO and those with MOG-IgG. The management and treatment of NMO/NMOSD involve various strategies, including addressing symptoms, managing acute relapses, and implementing long-term maintenance through immunosuppressive therapies. Symptomatic therapy encompasses the treatment of pain, fatigue, bowel/bladder issues, cognitive deficits, sexual dysfunction, and muscle spasms. Acute relapse management includes corticosteroid therapy and plasma exchange (PLEX). However, approximately 90% of patients may eventually experience relapses and/or develop permanent disabilities. Consequently, long-term symptom management with immunotherapy is crucial in NMO/NMOSD due to its association with relapse-related disability, unfavorable prognosis, and high mortality risk in untreated individuals. The FDA has granted approval to three drugs for NMO relapse treatment in adults: Eculizumab (Soliris, Elizaria), Satralizumab (Enspryng), and Inebilizumab (Uplizna).

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Neuromyelitis Optica (NMO) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034